Clinical Trials for Colon Cancer

8 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
OtherVICCGI0721
01/09/2007
Vanderbilt Hereditary Colorectal Cancer Registry
PreventionGIS0820-M
07/09/2013
A double blind placebo controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colon ca in patients with stage 0-III colon ca; phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac
Supportive CareVICCREACH1341
09/05/2013
Using a Tailored Navigation Intervention to Prepare Patients and Their Support Person for the Journey at Time of Cancer Diagnosis and at Transition into Survivorship
TreatmentVICCPHI1394
04/17/2014
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
TreatmentVICCBMT1381
01/23/2014
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Orbec? (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by Graft vs Host Disease (GVHD) in Patients with Chronic GI GVHD
TreatmentECOGGIS0820
09/03/2013
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
TreatmentVICCPHI1314
06/25/2013
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14- SN38, Antibody-Drug Conjugate) in Patients with Colorectal Cancer
TreatmentVICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

You do not have JavaScript enabled. This site works better with JavaScript turned on.